Back

Comparative efficacy of novel drugs as an addition to guideline-directed medical therapy for heart failure with reduced ejection fraction: a network meta-analysis of randomised controlled trials

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Heart failure pharmacology Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Mr Thanakit Suebsaicharoen

Ramathibodi Hospital of Mahidol University, Bangkok (Thailand)

6 More presentations in this session

Presentation thumbnail
Adherence and discontinuation of optimal heart failure therapies according to age
Miss C. Garred (Herlev, DK)
Abstract Slides
Presentation thumbnail
Maximally tolerated guideline-directed medical therapy and barriers to optimization in patients with heart failure with reduced ejection fraction: The COAPT trial
Associate Professor Z. Cox (Nashville, US)
Abstract Slides
Presentation thumbnail
Real-world eligibility for vericiguat according to trial, guideline, and labelling eligibility criteria: data from the Swedish Heart Failure Registry
Mr V. Nguyen (Stockholm, SE)
Abstract Slides
Presentation thumbnail
Efficacy of sodium glucose cotransporter 2 inhibitors for heart failure with preserved and mildly reduced ejection fraction: a systematic review and meta-analysis
Doctor K. Rivera (Manila, PH)
Abstract Slides
Presentation thumbnail
Compliance to guideline-recommended pharmacotherapy in patients with heart failure, 2014 to 2020
Doctor K. Odegaard (Oslo, NO)
Abstract Slides

Access the full session

Session thumbnail
Heart failure pharmacology

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources